ALNY Stock Price Today (July 2026) — Alnylam Pharmaceuticals, Inc. Analysis & Key Metrics 2026-07-17
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at $267.47, down 5.54% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $434.72 (62.5% upside).
- Volatility remains elevated (38.28% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (96.40% YoY) alongside significant competitive pressures.
ALNY Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Alnylam Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $40.15B
P/E Ratio
Forward P/E: 22.34
Revenue Growth
Year over Year
Analyst Target
+62.5% upside potential
Key Investor Questions About ALNY
What investors need to know before buying
Based on current market data, ALNY presents a oversold technical setup with caution warranted fundamentals.
- Technicals say: Oversold (RSI 29.06)
- Fundamentals say: Caution warranted (high leverage concerns)
ALNY's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ALNY investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.97B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ALNY stock traded between $273.11 and $495.55—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 38.28% annualized volatility and β=0.85, the stock exhibits moderate correlation to market moves—making ALNY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
Morgan Stanley Raises its Price Target on Alnylam (ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 10 Best Growth Stocks With Highest Upside Potential. On July 10, 2026, Morgan Stanley raised the firm’s price target on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $400 from $370 and kept an Equal Weight rating on the shares. On July 9, Raymond James raised the firm’s price target […]
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says
Alnylam Pharmaceuticals' (ALNY) Q2 financial results will be important in determining where 2026 rev
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
What It Means To Hold Moderna Stock In A Crash
The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?
Alnylam Pharmaceuticals (ALNY) has drawn fresh attention after shares moved sharply higher, helped by the late stage failure of a competing ATTR cardiomyopathy therapy from AstraZeneca and Ionis Pharmaceuticals, as well as recent collaboration updates. See our latest analysis for Alnylam Pharmaceuticals. Even after the recent surge following competitor trial setbacks and collaboration news, Alnylam Pharmaceuticals’ 1-day share price return declined 4.49%, capping a year to date share price...
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)?
In recent days, Alnylam Pharmaceuticals has benefited from the late-stage failure of AstraZeneca and Ionis’s competing ATTR-CM trial, alongside expanded AI and regional partnerships that deepen access to its RNAi therapies across new European markets. This setback for a key rival potentially enhances Alnylam’s competitive footing in transthyretin amyloid cardiomyopathy while its AI collaborations aim to sharpen commercial execution. We’ll now explore how the competitor trial failure in...
Alnylam (ALNY) Gets An Opening In ATTR CM As Rival Trial Fails
AstraZeneca and Ionis Pharma reported a failure in a late-stage ATTR-CM trial, removing a key competing approach in transthyretin cardiomyopathy. Alnylam Pharmaceuticals, ticker NasdaqGS:ALNY, now faces less late-stage competition in RNAi-based cardiomyopathy treatments. Alnylam has expanded its GENESIS Pharma collaboration, targeting broader geographic access for its RNAi portfolio. The company has also deepened AI-focused partnerships to support commercial execution and operational...
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.
Frequently Asked Questions
Common investor questions about Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $267.47. The RSI (14-day) is at 29.1, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $434.72 implies 62.5% upside from current levels. Volatility is moderate at 38.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Alnylam Pharmaceuticals, Inc. (ALNY): The trailing P/E ratio is 67.37, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 22.34, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.52, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 33.19. Price-to-Sales is 8.33. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering ALNY, the consensus price target is $434.72. This represents a 62.5% upside from the current price of $267.47. The range spans from a low target of $310.00 to a high target of $550.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Alnylam Pharmaceuticals, Inc. (ALNY) investors include: 1. Moderate volatility (38.3% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 276.20) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Alnylam Pharmaceuticals, Inc.'s (ALNY) current debt and financial health profile: Total debt stands at $2.97B. The debt-to-equity ratio is 276.20, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.13, indicating strong short-term liquidity. The quick ratio is 2.88. The company holds $3.01B in cash and equivalents. Free cash flow is positive at $204.71M, providing a cushion for debt servicing and shareholder returns.